

Xolair (omalizumab)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY <input type="checkbox"/> RENEWAL IF RENEWAL: DATE THERAPY INITIATED: _____			
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page



Xolair (omalizumab)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?		
<input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Chronic idiopathic urticaria(CIU) <input type="checkbox"/> Persistent asthma <input type="checkbox"/> Chronic rhinosinusitis with nasal polyps(CRSwNP), <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s):		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Is patient going to be using drug in a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Is the prescriber one of the following or in consultation with one of the following? <input type="checkbox"/> Yes <input type="checkbox"/> No (Please provide documentation)		
<input type="checkbox"/> Allergist <input type="checkbox"/> Immunologist <input type="checkbox"/> Dermatologist <input type="checkbox"/> Pulmonologist <input type="checkbox"/> Otolaryngologist		
Is patient receiving Xolair in combination with any of the following? <input type="checkbox"/> Yes <input type="checkbox"/> No		
<input type="checkbox"/> Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)] <input type="checkbox"/> Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)] <input type="checkbox"/> Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]		
<u>Initial Reques for Chronic idiopathic urticaria(CIU):</u>		
Have all other causes of urticaria(hives) such as allergies have been ruled out? <input type="checkbox"/> Yes <input type="checkbox"/> No (Please provide documentation)		
Has patient had chronic idiopathic urticaria or chronic spontaneous urticaria for at least 6 weeks or more? <input type="checkbox"/> Yes <input type="checkbox"/> No (Please provide documentation)		
Has patient tried and failed an antihistamine (H1 blocker) such as loratadine, cetirizine, diphenhydramine, and/or hydroxyzine? <input type="checkbox"/> Yes <input type="checkbox"/> No (Please provide documentation)		
Has patient tried and failed a Histamine- 2 blocker such as ranitidine, famotidine, cimetidine, and/or nizatidine? <input type="checkbox"/> Yes <input type="checkbox"/> No (Please provide documentation)		

Xolair (omalizumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Has patient tried a leukotriene receptor inhibitor such as montelukast and/or zafirlukast?
 Yes No (Please provide documentation)

Initial Request for Persistent Asthma:

Does patient have a diagnosis of moderate to severe persistent asthma? Yes No
(Please provide documentation)

Has patient had asthma for at least one year? Yes No (Please provide documentation)

Does patient have a positive skin test reaction to a perennial aeroallergen? Yes No
(Please provide documentation)

Does patient have a baseline plasma immunoglobulin E (IgE) level greater than or equal to 30 IU/mL and less than or equal to 1300 IU/mL? Yes No (Please provide documentation)

Is patient's classification of asthma as uncontrolled or inadequately controlled as defined by at least one of the following? Yes No (Please provide documentation)

- Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 month
- Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment)
- Airflow limitation (e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second [FEV1] less than 80% predicted [in the face of reduced FEV1/forced vital capacity [FVC] defined as less than the lower limit of normal])
- Patient is currently dependent on maintenance therapy with oral corticosteroids for the treatment of asthma

Will Xolair(omalizumab) be used in combination with one of the following: Yes No
(Please provide documentation)

- One maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2- agonist (LABA) product [e.g., Advair/AirDuo Respiclick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)].
 - Combination therapy including both of the following:
 - One maximally-dosed (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco®), mometasone furoate (Asmanex®), beclomethasone dipropionate (QVAR®)];
 - One additional asthma controller medication [e.g., LABA - olodaterol (Striverdi®) or indacaterol (Arcapta®); leukotriene receptor antagonist – montelukast (Singulair®); theophylline]

For new starts only, has patient had a 3-month trial of Nucala (Mepolizumab)? Yes No
(Please provide documentation)

Does patient have an absolute contraindication to Nucala(mepolizumab)? Yes No
(Please provide documentation)

For new starts only, has patient had a 3-month trial of Dupixent(dupilumab)? Yes No
Please provide documentation.

Xolair (omalizumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Does patient have an absolute contraindication to Dupixent(dupilumab)? Yes No
(Please provide documentation)

Initial Request for Chronic rhinosinusitis with nasal polyps(CRSwNP):

Does patient have a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP)? Yes No
(Please provide documentation)

Has patient been unable to obtain symptom relief after trial of an Intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)? Yes No (Please provide documentation)

Has patient been unable to obtain symptom relief after trial of one other therapy used in the management of nasal polyps [i.e., nasal saline irrigations, antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)]? Yes No (Please provide documentation)

Has patient required systemic corticosteroids (e.g., prednisone, methylprednisolone) for CRSwNP in the previous 2 years? Yes No (Please provide documentation)

Has patient required prior sinus surgery? Yes No (Please provide documentation)

Will patient receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)? Yes No

For new starts only, has patient had a 3-month trial of Dupixent(dupilumab)? Yes No
(Please provide documentation)

Does patient have an absolute contraindication to Dupixent(dupilumab)? Yes No
(Please provide documentation)

For new starts only, has patient had a 3-month trial of Nucala(Mepolizumab)? Yes No

Does patient have an absolute contraindication to Nucala(mepolizumab)? Yes No
(Please provide documentation)

Renewal Request:

Has patient demonstrated a reduction in severity of their disease/symptoms? Yes No
(Please provide documentation)

Is patient continuing to have clinical disease? Yes No (Please provide documentation)

Is patient receiving Xolair in combination with any of the following? Yes No

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

Xolair (omalizumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909